Table 1.
Baseline Characteristics of the Study Population and Univariate Associations with Poorer Physical Health
| Participant characteristic | N=1030 | OR [95% CI] |
|---|---|---|
| Age at diagnosis, mean±SD | 53.5±8.2 | 1.0 [0.99–1.0] |
| Years between diagnosis and study entry, mean±SD | 2.1±1.0 | 0.8 [0.7–0.9] |
| Ethnicity, n (%) | ||
| White | 886 (86.0) | Ref |
| Black | 29 (2.8) | 1.8 [0.8–3.7] |
| Hispanic | 49 (4.8) | 1.5 [0.8–2.7] |
| Asian | 34 (3.3) | 0.9 [0.4–1.8] |
| Other | 32 (3.1) | 0.9 [0.4–1.8] |
| BMI (kg/m2), mean±SD | 28.0±6.3 | |
| Normal weight(<25) | 385 (37.3) | Ref |
| Overweight (25–29.99) | 333 (32.3) | 1.4 [1.1–2.0] |
| Obese (>30) | 312 (30.3) | 3.0 [2.2–4.1] |
| Smoking (pack-years), n (%) | ||
| Never | 556 (54.0) | Ref |
| <20 | 316 (30.8) | 1.1 [0.8–1.4] |
| >20 | 152 (14.8) | 1.3 [0.9–1.9] |
| Alcohol consumption (>1 grams/day), n (%) | 412 (40.1) | 0.6 [0.5–0.8] |
| Tumor type, n (%) | ||
| Infiltrating ductal | 836 (81.2) | Ref |
| Infiltrating ductal and lobular invasive | 58 (5.6) | 0.8 [0.5–1.4] |
| Infiltrating lobular | 97 (9.4) | 1.2 [0.8–1.9] |
| Other | 39 (3.8) | 1.4 [0.7–2.6] |
| ER+, n (%) | 750 (74.0) | 1.0 [0.7–1.3] |
| PR+, n (%) | 649 (64.5) | 1.1 [0.9–1.5] |
| Breast cancer stage, n (%) | ||
| I | 295 (28.6) | Ref |
| II | 479 (46.5) | 1.3 [0.9–1.7] |
| III | 256 (24.9) | 1.6 [1.2–2.3] |
| Breast cancer subtype, n (%) | ||
| Luminal (ER+ or PR+) | 784 (76.1) | Ref |
| Her2 enriched (Her2+, ER–) | 54 (5.2) | 0.8 [0.5–1.4] |
| Triple negative (ER–, Pr- and Her2–) | 116 (11.3) | 0.9 [0.6–1.3] |
| Unspecified Receptors | 76 (7.4) | 1.2 [0.8–2.0] |
| Chemotherapy, n (%) | 741 (72.0) | 1.3 [1.0–1.7] |
| Tamoxifen use (current), n (%) | 643 (61.6) | 0.8 [0.6–1.1] |
| Physical activity (MET-hours/week) n(%) | ||
| ≤10 | 531 (51.6) | Ref |
| ≥10 | 499 (48.5) | 0.5 [0.4–0.6] |
| Estradiol level pg/mL, geometric mean±SD | 9.4±2.5 | 1.2 [1.0–1.3] |
| Bioavailable estradiol level pg/mL, geometric mean±SD | 4.7±3.2 | 1.1 [1.0–1.2] |
| Free estradiol level pg/mL, geometric mean±SD | 0.2±3.7 | 1.1 [1.0–1.2] |
ER, estrogen receptor; Her2, human epidermal growth factor receptor 2; MET, metabolic equivalent tasks; OR, odds ratio; CI, confidence interval; PR, progesterone receptor; SD, standard deviation.